Does Sapropterin Lower Phenylalanine Levels?
Sapropterin (Kuvan) reduces blood phenylalanine (Phe) levels in many patients with phenylketonuria (PKU) who respond to it. In clinical trials, about 20-50% of patients classified as responders saw Phe drop by at least 30% within 4 weeks at doses of 10-20 mg/kg/day.[1][2]
How Quickly Does It Work?
Response occurs rapidly: Phe levels often decrease within hours to days of starting treatment. In the Phase 3 PKU-004 trial, responders maintained reductions averaging 35-40% over 6 months when combined with a Phe-restricted diet.[1] Non-responders show no significant change.
Who Responds Best?
Patients with milder PKU (baseline Phe 360-2500 μmol/L) respond more often than those with severe forms. Genetic factors like specific PAH mutations predict response; testing via a 24-48 hour challenge dose identifies responders before long-term use.[2][3]
What If It Doesn't Work?
Around half of patients do not respond, requiring continued dietary management alone. No response means Phe stays elevated, risking neurotoxicity from chronic hyperphenylalaninemia.[1]
Long-Term Phe Control Data
In open-label extensions up to 10 years, responders sustained Phe below 360 μmol/L in 60-80% of cases, improving dietary freedom and quality of life.[3] Discontinuation often leads to Phe rebound within weeks.
Common Side Effects with Phe Reduction
Headache, rhinitis, and pharyngitis occur in 10-20% of users, but serious issues are rare. Monitoring Phe weekly during initiation ensures efficacy without overdose risks.[2]
[1]: FDA Label for Kuvan
[2]: BioMarin Clinical Overview
[3]: NEJM PKU-004 Trial